drugset
drugset / Trial / NCT05495061

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05495061 ↗

Phase 3 Completed 325 enrolled Santen Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.

Timeline

Start
2022-08-09
Primary completion
2023-04-18
Completion
2023-04-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Other
Subject Sepetaprost Small molecule 0.002 % Other

Indications

ocular hypertension open-angle glaucoma